Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cellectis
Biotech
Cellectis drops one of its 3 clinical-stage CAR-Ts
Cellectis has deprioritized one of its leukemia-focused candidates in order to focus on its other two clinical-stage CAR-T therapies.
James Waldron
Nov 5, 2024 7:15am
AstraZeneca takes 22% stake in Cellectis under 10-asset collab
Nov 1, 2023 8:45am
Cellectis culls CAR-T over cost of kick-starting slow trial
May 5, 2023 8:20am
Mayo Clinic cell and gene therapy accelerator launches startup
Jan 3, 2023 9:50am
Servier severs CAR-T collab with Allogene
Sep 22, 2022 10:23am
SITC: Cellectis off-the-shelf CAR-T active in solid tumor models
Nov 12, 2021 10:50am
